8-K: AbbVie Reports Mixed Full-Year and Fourth-Quarter 2024 Results, Provides 2025 Guidance

AbbVie's full-year 2024 results show revenue growth but a decrease in earnings per share, while the fourth quarter saw a loss per share due to an impairment charge, with the company providing 2025 adjusted EPS guidance.

Summary

• AbbVie reported full-year 2024 net revenues of $56.334 billion, a 3.7% increase on a reported basis and 4.6% on an operational basis.
• Full-year diluted EPS was $2.39 on a GAAP basis, a 12.1% decrease, and adjusted diluted EPS was $10.12, an 8.9% decrease, which includes a $1.52 per share unfavorable impact from acquired IPR&D and milestones expense.
• The immunology portfolio generated $26.682 billion in global net revenues, a 2.1% increase on a reported basis, with Humira revenues at $8.993 billion, Skyrizi at $11.718 billion, and Rinvoq at $5.971 billion.
• The oncology portfolio's global net revenues were $6.555 billion, a 10.8% increase, with Imbruvica at $3.347 billion and Venclexta at $2.583 billion.
• The neuroscience portfolio saw global net revenues of $8.999 billion, a 16.6% increase, with Botox Therapeutic at $3.283 billion and Vraylar at $3.267 billion.
• The aesthetics portfolio's global net revenues were $5.176 billion, a 2.2% decrease, with Botox Cosmetic at $2.720 billion and Juvederm at $1.177 billion.
• Fourth-quarter net revenues were $15.102 billion, a 5.6% increase on a reported basis and 6.1% on an operational basis.
• The fourth-quarter diluted loss per share was $0.02 on a GAAP basis, including an impairment charge related to emraclidine, while adjusted diluted EPS was $2.16, which includes a $0.88 per share unfavorable impact from acquired IPR&D and milestones expense.
• AbbVie provides 2025 adjusted diluted EPS guidance of $12.12 to $12.32, excluding any unfavorable impact related to acquired IPR&D and milestones expense.
• The company reaffirms expectations for high single-digit compound annual revenue growth through 2029 and raises the 2027 combined sales outlook for Skyrizi and Rinvoq to more than $31 billion.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative due to mixed results. While there is strong growth in some areas, the decrease in EPS, the loss in the fourth quarter, and the impairment charge are concerning. The long-term outlook is positive, but there are significant challenges to overcome.

Positives

• AbbVie's net revenues increased for both the full year and the fourth quarter.
• Skyrizi and Rinvoq demonstrated strong growth in both full-year and fourth-quarter revenues.
• The neuroscience portfolio showed significant revenue growth.
• AbbVie has reaffirmed its long-term revenue growth expectations.
• The company has raised its combined sales outlook for Skyrizi and Rinvoq for 2027.
• The aesthetics portfolio is expected to see high single-digit growth from 2025 through 2029.
• AbbVie completed several strategic acquisitions to strengthen its pipeline and R&D capabilities.

Negatives

• Full-year diluted EPS decreased by 12.1% on a GAAP basis and 8.9% on an adjusted basis.
• The company experienced a diluted loss per share in the fourth quarter on a GAAP basis.
• The fourth-quarter results included a significant unfavorable impact from acquired IPR&D and milestones expense.
• Humira revenues decreased significantly due to loss of exclusivity.
• The aesthetics portfolio experienced a decrease in full-year and fourth-quarter revenues.
• The company recorded a non-cash after-tax intangible asset impairment charge of $3.5 billion related to emraclidine.

Risks

• The loss of exclusivity for Humira is significantly impacting revenues.
• Acquired IPR&D and milestones expenses are negatively affecting earnings per share.
• The company is facing challenges in the aesthetics portfolio.
• The intangible asset impairment charge related to emraclidine has negatively impacted the company's financials.
• There are risks associated with the development and regulatory approval of new drugs.
• The company is exposed to litigation and regulatory risks.

Future Outlook

AbbVie provides 2025 adjusted diluted EPS guidance of $12.12 to $12.32, excluding any unfavorable impact related to acquired IPR&D and milestones expense, and reaffirms expectations for high single-digit compound annual revenue growth through 2029. The company also raised its 2027 combined sales outlook for Skyrizi and Rinvoq to more than $31 billion and updated its outlook for aesthetics to deliver high single-digit compound annual revenue growth from 2025 through 2029.

Management Comments

• Robert A. Michael, chief executive officer, stated that 2024 was a year of significant progress for AbbVie.
• He also mentioned that the company's growth platform delivered outstanding results, they advanced their pipeline, and strengthened their business through strategic transactions.
• He noted that AbbVie is entering 2025 with significant momentum and expects net revenues to exceed their previous peak in just the second full year following the U.S. Humira loss of exclusivity.

Industry Context

The results reflect the ongoing challenges and opportunities in the pharmaceutical industry, including the impact of patent expirations (Humira), the growth of new products (Skyrizi, Rinvoq), and the strategic importance of acquisitions and collaborations. The company's focus on immunology, oncology, neuroscience, and aesthetics aligns with key growth areas in the healthcare sector.

Comparison to Industry Standards

• AbbVie's performance is mixed when compared to industry standards. While the growth in Skyrizi and Rinvoq is impressive, the decline in Humira sales due to patent expiration is a significant headwind, similar to what other companies face with biosimilar competition.
• The company's adjusted EPS guidance for 2025 is a positive sign, but the impact of IPR&D expenses and the impairment charge are concerning. Companies like Johnson & Johnson and Pfizer also face similar challenges with patent cliffs and R&D investments.
• The aesthetics portfolio's performance is below expectations, which contrasts with the growth seen in other companies in the medical aesthetics market, such as Allergan (now part of AbbVie) and Galderma.
• The neuroscience portfolio's growth is a strong point, aligning with the increasing focus on neurological treatments in the pharmaceutical industry. Companies like Biogen and Eli Lilly are also heavily invested in this area.
• AbbVie's long-term revenue growth outlook is positive, but it will depend on the successful launch and uptake of new products and the management of biosimilar competition.

Stakeholder Impact

• Shareholders may be concerned about the decrease in EPS and the fourth-quarter loss, but encouraged by the long-term growth outlook.
• Employees may be affected by the company's strategic decisions and restructuring efforts.
• Customers will benefit from the development of new and innovative medicines.
• Suppliers may see changes in demand based on the company's product portfolio.
• Creditors will be monitoring the company's financial performance and debt levels.

Next Steps

• AbbVie will host an investor conference call to discuss the fourth-quarter performance.
• The company will continue to evaluate information with respect to the Cerevel-related clinical development programs.
• AbbVie remains on track to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for tavapadon later this year.

Key Dates

Keywords

AbbVie, Financial Results, Earnings Per Share, Revenue, Humira, Skyrizi, Rinvoq, Immunology, Oncology, Neuroscience, Aesthetics, Impairment, Guidance, Acquisition, Pharmaceuticals